KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
作者： Astrid Lièvre , Jean-Baptiste Bachet , Delphine Le Corre , Valérie Boige , Bruno Landi
DOI: 10.1158/0008-5472.CAN-06-0191
关键词:
摘要: … 30 metastatic colorectal cancer patients treated by cetuximab were screened for KRAS, BRAF, … (8) reported a prevalence of 15% in a series of 48 rectal cancers tested by FISH. These …
aacrjournals.org
highwire.org参考文章(11)
T Sauer, M G Guren, T Noren, S Dueland, Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti‐EGFR therapy? Histopathology. ,vol. 47, pp. 560- 564 ,(2005) , 10.1111/J.1365-2559.2005.02252.X
Jinru Shia, David S Klimstra, Allan R Li, Jing Qin, Leonard Saltz, Julie Teruya-Feldstein, Muzaffar Akram, Ki Young Chung, Davis Yao, Philip B Paty, William Gerald, Beiyun Chen, Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Modern Pathology. ,vol. 18, pp. 1350- 1356 ,(2005) , 10.1038/MODPATHOL.3800417
Deborah Schrag, The price tag on progress--chemotherapy for colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 317- 319 ,(2004) , 10.1056/NEJMP048143
Shuji Ogino, Jeffrey A. Meyerhardt, Mami Cantor, Mohan Brahmandam, Jeffrey W. Clark, Chungdak Namgyal, Takako Kawasaki, Kate Kinsella, Ann L. Michelini, Peter C. Enzinger, Matthew H. Kulke, David P. Ryan, Massimo Loda, Charles S. Fuchs, Molecular Alterations in Tumors and Response to Combination Chemotherapy with Gefitinib for Advanced Colorectal Cancer Clinical Cancer Research. ,vol. 11, pp. 6650- 6656 ,(2005) , 10.1158/1078-0432.CCR-05-0738
William Pao, Theresa Y Wang, Gregory J Riely, Vincent A Miller, Qiulu Pan, Marc Ladanyi, Maureen F Zakowski, Robert T Heelan, Mark G Kris, Harold E Varmus, KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib PLOS Medicine. ,vol. 2, ,(2005) , 10.1371/JOURNAL.PMED.0020017
Mauro Moroni, Silvio Veronese, Silvia Benvenuti, Giovanna Marrapese, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Marcello Gambacorta, Salvatore Siena, Alberto Bardelli, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncology. ,vol. 6, pp. 279- 286 ,(2005) , 10.1016/S1470-2045(05)70102-9
Yardena Samuels, Zhenghe Wang, Alberto Bardelli, Natalie Silliman, Janine Ptak, Steve Szabo, Hai Yan, Adi Gazdar, Steven M Powell, Gregory J Riggins, James KV Willson, Sanford Markowitz, Kenneth W Kinzler, Bert Vogelstein, Victor E Velculescu, High Frequency of Mutations of the PIK3CA Gene in Human Cancers Science. ,vol. 304, pp. 554- 554 ,(2004) , 10.1126/SCIENCE.1096502
H Jervoise N Andreyev, Andrew R Norman, Paul A Clarke, David Cunningham, Jacqueline R Oates, None, Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter “RASCAL” Study Journal of the National Cancer Institute. ,vol. 90, pp. 675- 684 ,(1998) , 10.1093/JNCI/90.9.675
David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, Eric Van Cutsem, None, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 351, pp. 337- 345 ,(2004) , 10.1056/NEJMOA033025
Ki Young Chung, Jinru Shia, Nancy E. Kemeny, Manish Shah, Gary K. Schwartz, Archie Tse, Audrey Hamilton, Dorothy Pan, Deborah Schrag, Lawrence Schwartz, David S. Klimstra, Daniel Fridman, David P. Kelsen, Leonard B. Saltz, Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry Journal of Clinical Oncology. ,vol. 23, pp. 1803- 1810 ,(2005) , 10.1200/JCO.2005.08.037